ArticleFrontiers in medicine2026
Comparative screening performance and multicenter validation of novel inflammatory biomarkers (NLR, SII, and CAR) for risk stratification of diabetic foot ulcer in patients with type 2 diabetes mellitus.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the screening performance of the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and C-reactive protein-to-albumin ratio (CAR) for risk stratification of diabetic foot ulcer (DFU) in patients with type 2 diabetes mellitus (T2DM), and to develop an integrated risk screening model with clinically applicable cutoff values. Methods: This multicenter retrospective cross-sectional study included hospitalized patients with T2DM from Dujiangyan People's Hospital and Chongqing University Fuling Hospital between January 2024 and December 2025. Demographic characteristics, clinical variables, and laboratory parameters were collected, and NLR, SII, and CAR were calculated. Univariate and multivariate logistic regression analyses were performed to identify risk factors associated with DFU, and these results were combined with random forest analysis for variable selection. Four risk screening models were subsequently constructed. Model discrimination was evaluated using receiver operating characteristic (ROC) curves, area under the curve (AUC), and DeLong's test. Optimal cutoff values were determined using the Youden index. Model stability was assessed using bootstrap resampling (1000 iterations). Calibration performance was evaluated using the Hosmer-Lemeshow test and calibration curves, while clinical utility was assessed by decision curve analysis (DCA). A prespecified sensitivity analysis excluding patients with moderate-to-severe DFU infection was performed. The Fuling cohort served as an independent external validation cohort, with the development-derived threshold fixed and applied without recalibration. Results: A total of 962 patients from the Dujiangyan cohort (161 with DFU, 16.7%) and 600 patients from the Fuling cohort (204 with DFU, 34.0%) were included. Multivariate logistic regression analysis demonstrated that CAR was significantly associated with DFU in both cohorts [Dujiangyan cohort: odds ratio (OR) per 0.1-unit increase = 1.029, 95% Conclusion: CAR is independently associated with prevalent DFU in hospitalized patients with T2DM, but its association is largely driven by acute infection-related inflammation. The integrated risk model demonstrated good internal discrimination and modest external performance, and may assist in cross-sectional risk stratification for hospitalized patients; however, local recalibration is recommended before clinical deployment, and prospective studies in non-infected populations are needed before broader implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.